Keros Therapeutics Stock Beta
KROS Stock | USD 68.69 2.38 3.59% |
Keros Therapeutics fundamentals help investors to digest information that contributes to Keros Therapeutics' financial success or failures. It also enables traders to predict the movement of Keros Stock. The fundamental analysis module provides a way to measure Keros Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Keros Therapeutics stock.
Keros | Beta |
Keros Therapeutics Company Beta Analysis
Keros Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Keros Therapeutics Beta | 1.24 |
Most of Keros Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Keros Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Keros Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Keros Therapeutics is extremely important. It helps to project a fair market value of Keros Stock properly, considering its historical fundamentals such as Beta. Since Keros Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Keros Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Keros Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Competition |
In accordance with the recently published financial statements, Keros Therapeutics has a Beta of 1.236. This is 43.72% higher than that of the Biotechnology sector and 11.08% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Keros Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Keros Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Keros Therapeutics could also be used in its relative valuation, which is a method of valuing Keros Therapeutics by comparing valuation metrics of similar companies.Keros Therapeutics is currently under evaluation in beta category among its peers.
Keros Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Keros Therapeutics from analyzing Keros Therapeutics' financial statements. These drivers represent accounts that assess Keros Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Keros Therapeutics' important valuation drivers and their relationship over time.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Enterprise Value | 172.6M | 828.8M | 1.1B | 946.3M | 854.1M | 545.9M |
Keros Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Keros Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Keros Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Keros Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Keros Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Keros Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Keros Therapeutics' value.Shares | Holocene Advisors, Lp | 2024-09-30 | 843.1 K | Woodline Partners Lp | 2024-09-30 | 763.5 K | Geode Capital Management, Llc | 2024-09-30 | 725.6 K | Braidwell Lp | 2024-09-30 | 707.2 K | Citadel Advisors Llc | 2024-09-30 | 704.9 K | Millennium Management Llc | 2024-09-30 | 573 K | Redmile Group, Llc | 2024-09-30 | 552.5 K | Paradigm Biocapital Advisors Lp | 2024-09-30 | 525 K | Adar1 Capital Management Llc | 2024-09-30 | 445.1 K | Fmr Inc | 2024-09-30 | 4.9 M | Blackrock Inc | 2024-06-30 | 2.5 M |
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Keros Therapeutics will likely underperform.
Keros Fundamentals
Return On Equity | -0.44 | ||||
Return On Asset | -0.28 | ||||
Operating Margin | (151.18) % | ||||
Current Valuation | 2.32 B | ||||
Shares Outstanding | 40.51 M | ||||
Shares Owned By Insiders | 5.40 % | ||||
Shares Owned By Institutions | 94.60 % | ||||
Number Of Shares Shorted | 2.22 M | ||||
Price To Book | 5.32 X | ||||
Price To Sales | 4,178 X | ||||
Revenue | 151 K | ||||
Gross Profit | (87.27 M) | ||||
EBITDA | (152.18 M) | ||||
Net Income | (152.99 M) | ||||
Cash And Equivalents | 215.62 M | ||||
Cash Per Share | 8.37 X | ||||
Total Debt | 14.44 M | ||||
Debt To Equity | 0 % | ||||
Current Ratio | 14.39 X | ||||
Book Value Per Share | 13.57 X | ||||
Cash Flow From Operations | (124.51 M) | ||||
Short Ratio | 5.73 X | ||||
Earnings Per Share | (5.22) X | ||||
Target Price | 91.46 | ||||
Number Of Employees | 160 | ||||
Beta | 1.24 | ||||
Market Capitalization | 2.72 B | ||||
Total Asset | 370.02 M | ||||
Retained Earnings | (381.43 M) | ||||
Working Capital | 322.92 M | ||||
Current Asset | 11.95 M | ||||
Current Liabilities | 5.72 M | ||||
Net Asset | 370.02 M |
About Keros Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Keros Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Keros Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Keros Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.